
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is set to have a strong first quarter as their Growth Products show positive trends, and the management team has confidence in the growth of their drug Eliquis. With a focus on attracting investors, the company plans to continue their research and development efforts in their core therapeutic areas, while also seeking out new potential treatments such as their CELMoDs. Additionally, recent positive updates, such as BMY's guidance ahead of consensus and positive results from Bayer's asundexian trial, have increased the company's transformative potential and make it a strong buy for investors.
Bears say
Bristol-Myers Squibb is facing potential downside risks due to the possibility of more successful Phase 3 results from competitors in rare cardiovascular, inflammatory and oncology areas, as well as the risk of their own pipeline programs failing in clinical trials. Additionally, potential delays in regulatory approvals and any adverse macroeconomic or policy-related developments could also negatively impact the company's financial performance. As a result, the financial analyst has a negative outlook on the stock, despite the company's strong position in the immuno-oncology space.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares